FDOPA PET-CT of Nonenhancing Brain Tumors
Authors:
- Céline HeimburgerCHCéline Heimburger
- Alessio ImperialeAIAlessio Imperiale
- Benoît LhermitteBLBenoît Lhermitte
- Marie-Pierre ChenardMCMarie-Pierre Chenard
- François LefebvreFLFrançois Lefebvre
- Stéphane KremerSKStéphane Kremer
- François ProustFPFrançois Proust
- Izzie-Jacques NamerINIzzie-Jacques Namer
- 1 April 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 42 (4) , 250-257
Abstract
Primary brain tumor grading is crucial to rapidly determine the therapeutic impact and prognosis of a brain tumor as well as the tumors’ aggressiveness profile. On magnetic resonance imaging, high-grade tumors are usually responsible for blood -brain barrier breakdowns, which result in tumor enhancement. However, this is not always the case. The main objective of this study was to evaluate the diagnostic value of FDOPA PET in the assessment of primary brain tumor aggressiveness with no contrast enhancement on MRI. Fifty-three patients were prospectively included: 35 low-grade and 18 high-grade histologically proven gliomas, with no contrast enhancement. Each patient underwent static PET acquisitions at 30 minutes. All patients had MRSI with measurements of different metabolites ratio. FDOPA was useful in the subgroup of low-grade gliomas, discriminating between dysembryoplastic neuroepithelial tumor and grade II oligodendroglioma (P < 0.01). An optimal threshold of the maximum standardized uptake value at 30 minutes (SUVmax (T/N)30) = 2.16 to discriminated low- from high-grade gliomas with a sensitivity of 60%, specificity of 100%, PPV of 100%, and NPV of 83.33% (P < 0.01). The nCho/Cr and nCho/NAA ratios were significantly higher in high- than in low-grade gliomas (P < 0.03 and P < 0.04, respectively). A significant positive correlation between MRSI ratios and SUVmax was found. Including data from amino acid metabolism used alone or in association with MRSI allows us to discriminate between dysembryoplastic neuroepithelial tumor and grade II oligodendroglioma and between low- and high-grade gliomas with no contrast enhancement on MRI.Keywords
This publication has 29 references indexed in Scilit:
- Advanced MRI and PET imaging for assessment of treatment response in patients with gliomasThe Lancet Neurology, 2010
- Prognostic significance of contrast-enhancing low-grade gliomas in adults and a review of the literatureNeurological Research, 2009
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- 11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PETEuropean Journal of Nuclear Medicine and Molecular Imaging, 2004
- How often are nonenhancing supratentorial gliomas malignant? A population studyNeurology, 2002
- Blood-brain barrier and neuronal membrane transport of 6-[18F]fluoro-l-DOPA11Abbreviations: AAAD, aromatic l-amino acid decarboxylase; BBB, blood-brain barrier; BUI, brain uptake index; carbidopa, l-α-hydrazino-α-methyl-β-(3,4-dihydroxyphenyl)propionic acid; l-DOPA, l-3,4-dihydroxyphenylalanine; FDA, 6-fluorodopamine; [18F]FDOPA, 6-[18F]fluoro-l-3,4-dihydroxyphenylalanine; 4-[18F]FMT, 4-[18F]fluoro-l-meta-tyrosine; 6-[18F]FMT, 6-[18F]fluoro-l-meta-tyrosine; MeAIB, α-(methylamino)isobutyric acid; MPTP, 1-methyl-1,2,3,6-tetrahydropyridine; PD, Parkinson’s disease; PET, positron emission tomography; and PLP, pyridoxal phosphate.Biochemical Pharmacology, 2001
- The Significance of Lack of MR Contrast Enhancement of Supratentorial Brain Tumors in Adults: Histopathological Evaluation of a SeriesSurgical Neurology, 1998
- Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteriaJournal of Neuro-Oncology, 1997
- Grading of astrocytomas: A simple and reproducible methodCancer, 1988
- Dysembryoplastic Neuroepithelial Tumor: A Surgically Curable Tumor of Young Patients with Intractable Partial SeizuresNeurosurgery, 1988